A detailed history of Berger Financial Group, Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Berger Financial Group, Inc holds 2,856 shares of LLY stock, worth $2.56 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
2,856
Previous 2,752 3.78%
Holding current value
$2.56 Million
Previous $1.6 Million 38.47%
% of portfolio
0.21%
Previous 0.18%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

BUY
$592.2 - $792.28 $61,588 - $82,397
104 Added 3.78%
2,856 $2.22 Million
Q4 2023

Feb 07, 2024

SELL
$525.19 - $619.13 $19,432 - $22,907
-37 Reduced 1.33%
2,752 $1.6 Million
Q3 2023

Nov 03, 2023

BUY
$434.7 - $599.3 $6,085 - $8,390
14 Added 0.5%
2,789 $1.5 Million
Q2 2023

Aug 10, 2023

SELL
$350.74 - $468.98 $28,760 - $38,456
-82 Reduced 2.87%
2,775 $1.3 Million
Q1 2023

Apr 24, 2023

BUY
$310.63 - $364.82 $140,715 - $165,263
453 Added 18.84%
2,857 $981,000
Q4 2022

Jan 30, 2023

BUY
$321.55 - $374.67 $119,295 - $139,002
371 Added 18.25%
2,404 $879,000
Q3 2022

Oct 27, 2022

BUY
$296.48 - $337.87 $176,109 - $200,694
594 Added 41.28%
2,033 $657,000
Q2 2022

Aug 08, 2022

BUY
$278.73 - $327.27 $11,149 - $13,090
40 Added 2.86%
1,439 $467,000
Q1 2022

May 10, 2022

SELL
$234.69 - $291.66 $37,315 - $46,373
-159 Reduced 10.21%
1,399 $401,000
Q4 2021

Jan 26, 2022

BUY
$224.85 - $279.04 $34,402 - $42,693
153 Added 10.89%
1,558 $430,000
Q3 2021

Oct 28, 2021

BUY
$221.6 - $272.71 $43,212 - $53,178
195 Added 16.12%
1,405 $325,000
Q2 2021

Jul 29, 2021

SELL
$180.55 - $233.54 $38,637 - $49,977
-214 Reduced 15.03%
1,210 $278,000
Q1 2021

May 12, 2021

BUY
$164.32 - $212.72 $10,187 - $13,188
62 Added 4.55%
1,424 $266,000
Q4 2020

Feb 02, 2021

BUY
$130.46 - $172.63 $177,686 - $235,122
1,362 New
1,362 $230,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $853B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Berger Financial Group, Inc Portfolio

Follow Berger Financial Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Berger Financial Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Berger Financial Group, Inc with notifications on news.